Ruxolitinib
Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
| Trivial name | INCB018424 |
| Catalog Number | S1378 |
| Molecular Formula | C27H37Cl2N3O3 |
| CAS# | 941678-49-5 |
| Inchi | InChI=1S/C27H35N3O3.2ClH/c1-2-14-29(13-1)17-5-19-31-23-9-7-22(8-10-23)27-28-25-12-11-24(21-26(25)33-27)32-20-6-18-30-15-3-4-16-30;;/h7-12,21H,1-6,13-20H2;2*1H |
| Inchi Key | DQOUZINBHKWGGM-UHFFFAOYSA-N |
| SMILES | C1CCN(C1)CCCOC2=CC=C(C=C2)C3=NC4=C(O3)C=C(C=C4)OCCCN5CCCC5.Cl.Cl |
| Size | 25mg |
| Supplier Page | http://www.selleckchem.com/products/INCB18424.html |
| Additional Information | https://file.selleck.cn/downloads/struct/s1378-ruxolitinib-incb018424-chemical-structure.png |